MARKET

INNMF

INNMF

Amplia Therapeutics Ltd
OTCMQB
0.100
NaN%
Opening 09:30 02/13 EST
OPEN
--
PREV CLOSE
0.100
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.240
52 WEEK LOW
0.029
MARKET CAP
51.31M
P/E (TTM)
-7.4074
1D
5D
1M
3M
1Y
5Y
1D
AMPLIA THERAPEUTICS ANNOUNCES OPENING OF US SITES FOR AMPLICITY PANCREATIC CANCER TRIAL
Reuters · 2d ago
Amplia Expands U.S. Footprint With New Sites for Pancreatic Cancer Trial
TipRanks · 2d ago
Amplia Therapeutics Secures Key US Patent for Narmafotinib, Extending Protection to 2040
Reuters · 01/30 13:45
Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
Barchart · 01/30 07:45
Amplia Secures Phase 3-Ready Supply with First Large-Scale Narmafotinib Manufacture
TipRanks · 01/21 21:38
Amplia Therapeutics Reports Promising Phase 2a Trial Results for Narmafotinib in Pancreatic Cancer
Reuters · 01/12 13:45
Amplia Showcases Promising Pancreatic Cancer Data for Narmafotinib at ASCO GI
TipRanks · 01/09 05:37
Amplia Therapeutics Announces Phase 2a Results for Narmafotinib in Metastatic Pancreatic Cancer Trial
Reuters · 12/23/2025 13:45
More
About INNMF
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.

Webull offers Amplia Therapeutics Ltd stock information, including OTCMQB: INNMF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INNMF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INNMF stock methods without spending real money on the virtual paper trading platform.